Delving into the Latest Updates on Acerand Therapeutics (Shanghai) Co., Ltd. with Synapse

Overview

Tags

Neoplasms

Other Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

SOS1(Son of sevenless homolog 1)	1
PARP1(Poly (ADP-Ribose) polymerase 1)	1
CYP11A1(Cytochrome P450 11A1)	1

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 27 Jun 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Preclinical

1

IND Application

IND Approval

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

ACE-86225106 ( PARP1 )	Advanced Malignant Solid Neoplasm More	Phase 1/2
ACE-16229210 ( FGFR2 )	Advanced Malignant Solid Neoplasm More	IND Approval
ACE-232 ( CYP11A1 )	Adrenocortical Carcinoma More	Preclinical
ACE-47228211 ( SOS1 )	Neoplasms More	Preclinical